C-reactive protein and 5-year survival in type 2 diabetes: the Casale Monferrato Study
- PMID: 19074985
- PMCID: PMC2661603
- DOI: 10.2337/db08-0900
C-reactive protein and 5-year survival in type 2 diabetes: the Casale Monferrato Study
Abstract
Objective: To determine to what extent plasma C-reactive protein (CRP) values influence 5-year all-cause and cardiovascular mortality in type 2 diabetic individuals, independently of albumin excretion rate (AER) and other cardiovascular risk factors, and its incremental usefulness for predicting individual risk of mortality.
Research design and methods: Measurements of CRP were performed in 2,381 of 3,249 (73.3%) subjects as part of the population-based Casale Monferrato Study. Its association with 5-year all-cause and cardiovascular mortality was assessed with multivariate Cox proportional hazards modeling. The C statistic and measures of calibration and global fit were also assessed.
Results: Results are based on 496 deaths in 11.717 person-years of observations (median follow-up 5.4 years). With respect to subjects with CRP < or =3 mg/l, those with higher values had an adjusted hazard ratio (HR) of 1.51 (95% CI 1.18-1.92) for all-cause mortality and 1.44 (0.99-2.08) for cardiovascular mortality. In normoalbuminuric subjects, respective HRs of CRP were 1.56 (1.13-2.15) and 1.65 (1.00-2.74), AER being neither a modifier nor a confounder of CRP association. In analysis limited to diabetic subjects without cardiovascular disease (CVD), adjusted HRs were 1.67 (1.24-2.24) for all-cause mortality and 1.36 (0.83-2.24) for cardiovascular mortality. The improvement in individual risk assessment was marginal when measured with various statistical measures of model discrimination, calibration, and global fit.
Conclusions: CRP measurement is independently associated with short-term mortality risk in type 2 diabetic individuals, even in normoalbuminuric subjects and in those without a previous diagnosis of CVD. Its clinical usefulness in individual assessment of 5-year risk of mortality, however, is limited.
Figures
Comment in
-
C-reactive protein and prognosis in diabetes: getting to the heart of the matter.Diabetes. 2009 Apr;58(4):798-9. doi: 10.2337/db08-1788. Diabetes. 2009. PMID: 19336689 Free PMC article. No abstract available.
Similar articles
-
N-terminal probrain natriuretic peptide is a stronger predictor of cardiovascular mortality than C-reactive protein and albumin excretion rate in elderly patients with type 2 diabetes: the Casale Monferrato population-based study.Diabetes Care. 2013 Sep;36(9):2677-82. doi: 10.2337/dc13-0353. Epub 2013 Apr 5. Diabetes Care. 2013. PMID: 23564918 Free PMC article.
-
Fibrinogen and AER are major independent predictors of 11-year cardiovascular mortality in type 2 diabetes: the Casale Monferrato Study.Diabetologia. 2005 Mar;48(3):427-34. doi: 10.1007/s00125-004-1667-1. Epub 2005 Feb 5. Diabetologia. 2005. PMID: 15696295
-
Obesity is associated with lower mortality risk in elderly diabetic subjects: the Casale Monferrato study.Acta Diabetol. 2013 Aug;50(4):563-8. doi: 10.1007/s00592-011-0338-1. Epub 2011 Nov 9. Acta Diabetol. 2013. PMID: 22068621
-
The connection between C-reactive protein (CRP) and diabetic vasculopathy. Focus on preclinical findings.Curr Diabetes Rev. 2010 Jan;6(1):27-34. doi: 10.2174/157339910790442628. Curr Diabetes Rev. 2010. PMID: 20034371 Review.
-
Lowering HbA1c in type 2 diabetics results in reduced risk of coronary heart disease and all-cause mortality.Prim Care Diabetes. 2008 Feb;2(1):45-9. doi: 10.1016/j.pcd.2007.12.004. Epub 2008 Feb 8. Prim Care Diabetes. 2008. PMID: 18684420 Review.
Cited by
-
N-terminal probrain natriuretic peptide is a stronger predictor of cardiovascular mortality than C-reactive protein and albumin excretion rate in elderly patients with type 2 diabetes: the Casale Monferrato population-based study.Diabetes Care. 2013 Sep;36(9):2677-82. doi: 10.2337/dc13-0353. Epub 2013 Apr 5. Diabetes Care. 2013. PMID: 23564918 Free PMC article.
-
Effect of atorvastatin on C-reactive protein and benefits for cardiovascular disease in patients with type 2 diabetes: analyses from the Collaborative Atorvastatin Diabetes Trial.Diabetologia. 2015 Jul;58(7):1494-502. doi: 10.1007/s00125-015-3586-8. Epub 2015 Apr 22. Diabetologia. 2015. PMID: 25899452 Free PMC article. Clinical Trial.
-
Low-grade inflammation as a risk factor for cardiovascular events and all-cause mortality in patients with type 2 diabetes.Cardiovasc Diabetol. 2021 Nov 9;20(1):220. doi: 10.1186/s12933-021-01409-0. Cardiovasc Diabetol. 2021. PMID: 34753497 Free PMC article.
-
NT-proBNP linking low-moderately impaired renal function and cardiovascular mortality in diabetic patients: the population-based Casale Monferrato Study.PLoS One. 2014 Dec 11;9(12):e114855. doi: 10.1371/journal.pone.0114855. eCollection 2014. PLoS One. 2014. PMID: 25503636 Free PMC article.
-
Exercise and Type 1 Diabetes.Adv Exp Med Biol. 2020;1228:107-121. doi: 10.1007/978-981-15-1792-1_7. Adv Exp Med Biol. 2020. PMID: 32342453 Review.
References
-
- Hansson GK: Inflammation, atheroclerosis and coronary artery disease. N Engl J Med 352: 1685– 1695, 2005 - PubMed
-
- Pai JK, Pischon T, Ma J, Manson JE, Hankinson SE, Joshipura K, Curhan GC, Rifai N, Cannuscio CC, Stampfer MJ, Rimm EB: Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med 351: 2599– 2610, 2004 - PubMed
-
- Ridker PM, Wilson PW, Grundy SM: Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? Circulation 109: 2818– 2825, 2004 - PubMed
-
- Schulze MB, Rimm EB, Li T, Rifai N, Stampfer MJ, Hu FB: C-reactive protein and incident cardiovascular events among men with diabetes. Diabetes Care 27: 889– 894, 2004 - PubMed
-
- Pasceri V, Willersone JT, Yeh ET: Direct proinflamnatory effect of C-reactive protein on human endothelial cells. Circulation 102: 2165– 2168, 2000 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous